BACKGROUND: Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence. We assessed the efficacy of temozolomide as second-line therapy following failure of PCV chemotherapy in patients with recurrent/progressive gliomas. PATIENTS AND METHODS: Between September 1994 and November 2000, 32 patients with high-grade gliomas at second recurrence/progression received temozolomide as salvage therapy and results were reviewed retrospectively. RESULTS: Of 32 assessable patients 7 had clinical improvement; there were no imaging responses. Median survival of the cohort was 4 months, with 28% alive at 6 months. Age, performance status, histology and previous response to PCV chemotherapy did not predict for clinical response to temozolomide. CONCLUSION: In the small cohort of patients with recurrent malignant glioma who failed PCV chemotherapy temozolomide demonstrated limited activity as second-line treatment although this remains within the confidence intervals of response seen in patients with glioblastoma.
BACKGROUND:Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence. We assessed the efficacy of temozolomide as second-line therapy following failure of PCV chemotherapy in patients with recurrent/progressive gliomas. PATIENTS AND METHODS: Between September 1994 and November 2000, 32 patients with high-grade gliomas at second recurrence/progression received temozolomide as salvage therapy and results were reviewed retrospectively. RESULTS: Of 32 assessable patients 7 had clinical improvement; there were no imaging responses. Median survival of the cohort was 4 months, with 28% alive at 6 months. Age, performance status, histology and previous response to PCV chemotherapy did not predict for clinical response to temozolomide. CONCLUSION: In the small cohort of patients with recurrent malignant glioma who failed PCV chemotherapy temozolomide demonstrated limited activity as second-line treatment although this remains within the confidence intervals of response seen in patients with glioblastoma.
Authors: M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen Journal: Ann Oncol Date: 2001-02 Impact factor: 32.976
Authors: E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: M Bower; E S Newlands; N M Bleehen; M Brada; R J Begent; H Calvert; I Colquhoun; P Lewis; M H Brampton Journal: Cancer Chemother Pharmacol Date: 1997 Impact factor: 3.333
Authors: M Brada; I Judson; P Beale; S Moore; P Reidenberg; P Statkevich; M Dugan; V Batra; D Cutler Journal: Br J Cancer Date: 1999-11 Impact factor: 7.640
Authors: W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin Journal: Br J Cancer Date: 2000-09 Impact factor: 7.640
Authors: E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton Journal: Br J Cancer Date: 1992-02 Impact factor: 7.640
Authors: A Boiardi; M Eoli; A Salmaggi; E Lamperti; A Botturi; G Broggi; L Bissola; G Finocchiaro; A Silvani Journal: J Neurooncol Date: 2005-11 Impact factor: 4.130
Authors: Henry E Aryan; Hal S Meltzer; Daniel C Lu; Burak M Ozgur; Michael L Levy; Derek A Bruce Journal: Childs Nerv Syst Date: 2004-09-15 Impact factor: 1.475
Authors: Sudheer R Thumma; Ameer L Elaimy; Nathan Daines; Alexander R Mackay; Wayne T Lamoreaux; Robert K Fairbanks; John J Demakas; Barton S Cooke; Christopher M Lee Journal: Case Rep Med Date: 2012-04-04